SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001445305-14-005006
Filing Date
2014-11-10
Accepted
2014-11-10 16:09:44
Documents
10
Period of Report
2014-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20140930x10q.htm 10-Q 794429
2 EXHIBIT 31.1 mrtx93014ex311.htm EX-31.1 11514
3 EXHIBIT 31.2 mrtx93014ex312.htm EX-31.2 12244
4 EXHIBIT 32.1 mrtx93014ex321.htm EX-32.1 8021
  Complete submission text file 0001445305-14-005006.txt   4962336

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT mrtx-20140930.xml EX-101.INS 778740
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20140930.xsd EX-101.SCH 32502
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20140930_cal.xml EX-101.CAL 59140
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20140930_def.xml EX-101.DEF 96209
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20140930_lab.xml EX-101.LAB 380988
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20140930_pre.xml EX-101.PRE 201694
Mailing Address 9363 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9363 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 (514) 337-3333
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 141208743
SIC: 2834 Pharmaceutical Preparations